Melanie Silinski

Melanie Silinski, PhD, is an Analytical Chemist with expertise in mass spectrometry and chromatography with applications in drug discovery and development, from early exploratory research through investigational new drugs. She specializes in method development and the quantitative analysis of drug substances in biological matrices, as well as structure elucidation and metabolite identification using accurate mass spectrometric and tandem mass spectrometric techniques.

Dr. Silinski serves as a task leader for the National Toxicology Program Chemistry Services project, which includes determining the identity and purity of test articles, analysis of dose formulations, and analysis of biological samples from toxicology studies. She regularly conducts studies subject to GLP regulations, prepares SOPs, reviews data and reports, and has been an author or coauthor of dozens of peer-reviewed manuscripts.

Previously, Dr. Silinski worked as a research investigator at Serenex where she used state-of-the-art mass spectrometry and de novo sequencing to identify protein targets from a novel drug discovery screening platform, and performed the bioanalytical, absorption, distribution, metabolism, and excretion (ADME), and pre-formulation characterization studies in support of a small molecule clinical candidate. While in school she held research and teaching assistant positions at Duke University and Colgate University.